Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World Psilocybin Use

被引:0
作者
Mathai, David S. [1 ,2 ,3 ]
Roberts, Daniel E. [4 ]
Nayak, Sandeep M. [5 ]
Sepeda, Nathan D. [5 ,6 ]
Lehrner, Amy [8 ]
Johnson, Matthew W. [7 ,9 ]
Lowe, Matthew X. [10 ]
Jackson, Heather [10 ]
Garcia-Romeu, Albert [5 ]
机构
[1] Baylor Coll Med, Ctr Med Eth & Hlth Policy, Ethical Legal Implicat Psychedel Soc Program, Houston, TX USA
[2] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX USA
[3] Sattva Med, Psychiat Psychotherapy & Consulting Practice, 2121 Biscayne Blvd 1255, Miami, FL 33137 USA
[4] New York Univ, Ctr Psychedel Med, Dept Psychiat, Grossman Sch Med, New York, NY USA
[5] Johns Hopkins Univ, Ctr Psychedel & Consciousness Res, Dept Psychiat & Behav Sci, Sch Med, Baltimore, MD USA
[6] Ohio State Univ, Coll Social Work, Ctr Psychedel Drug Res & Educ, Columbus, OH USA
[7] Icahn Sch Med Mt Sinai, Ctr Psychedel Psychotherapy & Trauma Res, Dept Psychiat, New York, NY USA
[8] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Sch Med, Baltimore, MD USA
[9] Ctr Excellence Psilocybin Res & Treatment, Sheppard Pratt, Colorado Springs, CO USA
[10] Unltd Sci, Colorado Springs, CO USA
关键词
psychedelics; psilocybin; shame; challenging experience; emotional breakthrough; ASSISTED PSYCHOTHERAPY; CHALLENGING EXPERIENCES; ANXIETY; QUESTIONNAIRE; DRUGS; SELF; VALIDATION; THERAPY;
D O I
10.1080/02791072.2025.2461997
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
The classic psychedelic psilocybin has attracted special interest across clinical and non-clinical settings as a potential tool for mental health. Despite increasing attention to challenging psychedelic experiences, few studies have explored the relevance of shame-related processes with psychedelic use. This prospective, longitudinal study involved sequential, automated, web-based surveys that collected data from 679 adults planning to use psilocybin in naturalistic settings at timepoints before and after psilocybin use. State and trait shame and feelings of guilt were collected using validated measures and assessed alongside other measurements of psychological health. Acute feelings of shame or guilt during psilocybin experiences were commonly reported (68.2% of users) and difficult to predict. Ratings of participant ability to constructively work through these feelings predicted wellbeing 2-4 weeks after psilocybin use. Psilocybin on average produced a small but significant decrease in trait shame that was maintained 2-3 months after use (Cohen's dz = 0.37). Trait shame increased in a notable minority of participants (29.8%). The activation of self-conscious emotions with psychedelics deserves further attention as a challenging experience subcategory that may be relevant to psychological outcomes. Such experiences could pose a unique and context-dependent learning condition for both therapeutic and detrimental forms of shame-related memory reconsolidation.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey
    Nayak, Sandeep M.
    Jackson, Hillary
    Sepeda, Nathan D.
    Mathai, David S.
    So, Sara
    Yaffe, Abigail
    Zaki, Hadi
    Brasher, Trey J.
    Lowe, Matthew X.
    Jolly, Del R. P.
    Barrett, Frederick S.
    Griffiths, Roland R.
    Strickland, Justin C.
    Johnson, Matthew W.
    Jackson, Heather
    Garcia-Romeu, Albert
    FRONTIERS IN PSYCHIATRY, 2023, 14
  • [2] Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey
    Kuc, Joanna
    Kettner, Hannes
    Rosas, Fernando
    Erritzoe, David
    Haijen, Eline
    Kaelen, Mendel
    Nutt, David
    Carhart-Harris, Robin L.
    PSYCHOPHARMACOLOGY, 2022, 239 (05) : 1425 - 1440
  • [3] Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey
    Stroud, Jack
    Rice, Charlotte
    Orsini, Aaron
    Schlosser, Marco
    Lee, Justine
    Mandy, Will
    Kamboj, Sunjeev K.
    PSYCHOPHARMACOLOGY, 2025, 242 (02) : 373 - 387
  • [4] Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey
    Joanna Kuc
    Hannes Kettner
    Fernando Rosas
    David Erritzoe
    Eline Haijen
    Mendel Kaelen
    David Nutt
    Robin L. Carhart-Harris
    Psychopharmacology, 2022, 239 : 1425 - 1440
  • [5] Real-World Experience in the Use of Immunosuppression for the Management of Inflammatory Eye Disease
    Azzopardi, Matthew
    Chong, Yu Jeat
    Sreekantam, Sreekanth
    Barry, Robert J.
    Poonit, Natraj
    Rauz, Saaeha
    Murray, Philip I.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2024,
  • [6] Real-world evidence of the collective effects of psychedelic therapy: Evaluating from the grassroots
    Noorani, Tehseen
    Liebert, Rachel Jane
    JOURNAL OF PSYCHEDELIC STUDIES, 2024, 8 (02): : 260 - 268
  • [7] HeartMate 3: Bridging from clinical trial experience to real-world use
    Goldstein, Daniel J.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2018, 156 (02) : 660 - 661
  • [8] Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study
    Barbut Siva, Jessica
    Barba, Tommaso
    Kettner, Hannes
    Kuc, Joanna
    Nutt, David J.
    Carhart-Harris, Robin
    Erritzoe, David
    JOURNAL OF PSYCHOPHARMACOLOGY, 2024, 38 (02) : 145 - 155
  • [9] Evolution of teriflunomide use in multiple sclerosis: A real-world experience
    Lorefice, L.
    Pilotto, S.
    Fenu, G.
    Cimino, P.
    Firinu, D.
    Frau, J.
    Murgia, F.
    Coghe, G.
    Cocco, E.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2022, 438
  • [10] From real-world electronic health record data to real-world results using artificial intelligence
    Knevel, Rachel
    Liao, Katherine P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (03) : 306 - 311